The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

1,2 The Phase 1 data shows that Lutetium (177 Lu) rhPSMA-10.1 Injection has ... the innovative approach taken on optimizing radioligand therapy by Blue Earth Therapeutics and the inventors of ...

Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177 ... for nuclear medicine and radiation therapy. The company offers a broad range of services ...